| Identification | Back Directory | [Name]
6-(diaminomethylideneamino)hexylcarbamoylmethyl N-[4-[[(3R)-3-aminobutyl]amino]butyl]carbamate | [CAS]
170368-04-4 | [Synonyms]
LF 15-0195
AnisperiMus
PZDPVSFZTKORSP-OAHLLOKOSA-N
6-(diaminomethylideneamino)hexylcarbamoylmethyl N-[4-[[(3R)-3-aminobutyl]amino]butyl]carbamate
Carbamic acid, N-[4-[[(3R)-3-aminobutyl]amino]butyl]-, 2-[[6-[(aminoiminomethyl)amino]hexyl]amino]-2-oxoethyl ester | [Molecular Formula]
C18H39N7O3 | [MDL Number]
MFCD19443787 | [MOL File]
170368-04-4.mol | [Molecular Weight]
401.55 |
| Hazard Information | Back Directory | [Uses]
Anisperimus (LF-150195) is an immunosuppressant with the activity of enhancing activation-induced T cell death. Anisperimus enhances the sensitivity of T cells to anti-CD95 antibodies and other inducers by promoting the activation of caspase-8 and caspase-10 at the level of the death-inducing signaling complex (DISC). Anisperimus also promotes the development of Foxp3-expressing regulatory CD4 T cells, thereby preventing central nervous system autoimmunity[1]. | [References]
[1] LF 15-0195 immunosuppressive agent enhances activation-induced T-cell death by facilitating caspase-8 and caspase-10 activation at the DISC level DOI:10.1182/blood-2002-02-0603 |
|
|